AI-generated content for informational purposes only. Not financial advice. Always do your own research.

AstraZeneca
4.5 1 vote

AstraZeneca

Visit

About

Anglo-Swedish pharmaceutical company and one of the world's largest drugmakers. Leading pipeline in oncology, cardiovascular, and respiratory therapies.

European Blue Chips

AstraZeneca is one of Europe's largest pharmaceutical companies, combining robust oncology and respiratory drug portfolios with an industry-leading R&D pipeline.

Pharmaceutical Stocks

AstraZeneca is a global pharmaceutical leader with a strong pipeline in oncology, cardiovascular, and respiratory therapies, consistently delivering above-industry revenue growth.

Key Financials AZN

Price $205.55
Change (1D) +0.50%
Change (30D) +123.59%
Change (60D) +129.92%
Change (90D) +140.44%
Change (180D) +192.06%
Change (1Y) +176.17%
Change (5Y) +307.76%
P/E Ratio 34.55
EPS (TTM) $5.95
52-Week Range $61.24 — $206.71
50-Day MA $120.02
Volume 2.50M

Data updated Feb 15 · Source: Twelve Data

4.5 1 vote

AI Reviews

🤖
Claude Opus 4.6 Anthropic
4.5 /5

AstraZeneca has established itself as one of the world's premier biopharmaceutical companies, with a robust oncology pipeline that drives much of its growth narrative. The stock has delivered extraordinary performance, trading near its 52-week high of $206.71 with remarkable gains across all timeframes " up over 176% year-over-year and 308% over five years.

The bull case centers on AZN's industry-leading oncology franchise (Tagrisso, Imfinzi, Enhertu), expanding rare disease portfolio via the Alexion acquisition, and consistent revenue growth. Management has targeted $80 billion in revenue by 2030, an ambitious but credible goal given pipeline depth.

However, the bear case warrants attention. The P/E ratio of 34.55 is elevated for a large-cap pharma, pricing in significant future growth. Key patent expirations loom in the late 2020s, and the recent price surge may leave limited near-term upside. Regulatory and pricing pressures across global markets remain persistent headwinds.

AstraZeneca is a high-quality pharmaceutical holding, though current valuations suggest investors should consider entry points carefully. The pipeline strength and diversification provide a solid long-term foundation.

Category Ratings

European Blue Chips
4.6
Pharmaceutical Stocks
4.4
Feb 15, 2026
AI-Generated Review Generated via Anthropic API. This is an automated evaluation, not a consumer review. Learn more
AstraZeneca Screenshot

Added: Feb 15, 2026

astrazeneca.com

Categories

European Blue Chips Pharmaceutical Stocks